Guard Therapeutics International AB
GUARD | ST
Overview
Corporate Details
- ISIN(s):
- SE0021181559
- LEI:
- 549300DTX7T87FGYG180
- Country:
- Sweden
- Address:
- Box 5216, 102 45 Stockholm
- Website:
- https://guardtherapeutics.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Guard Therapeutics International AB is a clinical-stage biotechnology company that identifies and develops new therapies for diseases with significant unmet medical needs, with a primary focus on kidney disease. The company's lead drug candidate, RMC-035, is based on the endogenous protein alpha-1-microglobulin (A1M). The treatment is being evaluated in a Phase 2b clinical study (POINTER) for its potential to protect against and treat acute kidney injury. Guard Therapeutics' strategy is to advance its pipeline through clinical development and eventual commercialization to address the high demand for effective treatments in nephrology.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Guard Therapeutics International AB.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Automate Your Workflow. Get a real-time feed of all Guard Therapeutics International AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Guard Therapeutics International AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
